Pharmacological inhibition of poly(ADP-ribose) polymerase inhibits angiogenesis

Biochemical and Biophysical Research Communications

Volumn 350, Issue 2, 2006, Pages 352-357

  Rajesh, Mohanraj ^a   Mukhopadhyay, Partha ^a   Bátkai, Sándor ^a   Godlewski, Grzegorz ^a   Haskó, György ^b   Liaudet, Lucas ^c   Pacher, Pál ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

3 AB; Angiogenesis; HUVEC; Migration; PJ 34; Poly(ADP ribose) polymerase (PARP); Proliferation; Tube formation

Indexed keywords

3 AMINOBENZAMIDE; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANGIOGENESIS INHIBITORS; BENZAMIDES; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; HUMANS; PHENANTHRENES; POLY(ADP-RIBOSE) POLYMERASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33749347804     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.09.049     Document Type: Article

References (31)

1. Virag L., and Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol. Rev. 54 (2002) 375-429
2. Jagtap P., and Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat. Rev. Drug Discov. 4 (2005) 421-440
3. Graziani G., Battaini F., and Zhang J. PARP-1 inhibition to treat cancer, ischemia, inflammation. Pharmacol. Res. 52 (2005) 1-4
4. Graziani G., and Szabo C. Clinical perspectives of PARP inhibitors. Pharmacol. Res. 52 (2005) 109-118
5. Tentori L., Leonetti C., Scarsella M., Muzi A., Mazzon E., Vergati M., Forini O., Lapidus R., Xu W., Dorio A.S., Zhang J., Cuzzocrea S., and Graziani G. Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma. FASEB J. 20 (2006) 1709-1711
6. De Soto J.A., Wang X., Tominaga Y., Wang R.H., Cao L., Qiao W., Li C., Xu X., Skoumbourdis A.P., Prindiville S.A., Thomas C.J., and Deng C.X. The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors. Int. J. Biol. Sci. 2 (2006) 179-185
7. De Soto J.A., and Deng C.X. PARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers?. Int. J. Med. Sci. 3 (2006) 117-123
8. Pacher P., Schulz R., Liaudet L., and Szabo C. Nitrosative stress and pharmacological modulation of heart failure. Trends Pharmacol. Sci. 26 (2005) 302-310
9. Cattaneo M.G., Pola S., Francescato P., Chillemi F., and Vicentini L.M. Human endostatin-derived synthetic peptides possess potent antiangiogenic properties in vitro and in vivo. Exp. Cell Res. 283 (2003) 230-236
10. Rajesh M., Kolmakova A., and Chatterjee S. Novel role of lactosylceramide in vascular endothelial growth factor-mediated angiogenesis in human endothelial cells. Circ. Res. 97 (2005) 796-804
11. Garcia Soriano F., Virag L., Jagtap P., Szabo E., Mabley J.G., Liaudet L., Marton A., Hoyt D.G., Murthy K.G., Salzman A.L., Southan G.J., and Szabo C. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat. Med. 7 (2001) 108-113
12. Soriano F.G., Pacher P., Mabley J., Liaudet L., and Szabo C. Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly(ADP-ribose) polymerase. Circ. Res. 89 (2001) 684-691
13. Jagtap P., Soriano F.G., Virag L., Liaudet L., Mabley J., Szabo E., Hasko G., Marton A., Lorigados C.B., Gallyas Jr. F., Sumegi B., Hoyt D.G., Baloglu E., VanDuzer J., Salzman A.L., Southan G.J., and Szabo C. Novel phenanthridinone inhibitors of poly (adenosine 5′-diphosphate-ribose) synthetase: potent cytoprotective and antishock agents. Crit. Care Med. 30 (2002) 1071-1082
14. Delaney C.A., Wang L.Z., Kyle S., White A.W., Calvert A.H., Curtin N.J., Durkacz B.W., Hostomsky Z., and Newell D.R. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin. Cancer Res. 6 (2000) 2860-2867
15. Tentori L., Portarena I., Vernole P., De Fabritiis P., Madaio R., Balduzzi A., Roy R., Bonmassar E., and Graziani G. Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components. Cancer Chemother Pharmacol. 47 (2001) 361-369
16. Canan Koch S.S., Thoresen L.H., Tikhe J.G., Maegley K.A., Almassy R.J., Li J., Yu X.H., Zook S.E., Kumpf R.A., Zhang C., Boritzki T.J., Mansour R.N., Zhang K.E., Ekker A., Calabrese C.R., Curtin N.J., Kyle S., Thomas H.D., Wang L.Z., Calvert A.H., Golding B.T., Griffin R.J., Newell D.R., Webber S.E., and Hostomsky Z. Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure. J. Med. Chem. 45 (2002) 4961-4974
17. Tentori L., Portarena I., Bonmassar E., and Graziani G. Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells. Cell Death Differ. 8 (2001) 457-469
18. Calabrese C.R., Batey M.A., Thomas H.D., Durkacz B.W., Wang L.Z., Kyle S., Skalitzky D., Li J., Zhang C., Boritzki T., Maegley K., Calvert A.H., Hostomsky Z., Newell D.R., and Curtin N.J. Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clin. Cancer Res. 9 (2003) 2711-2718
19. Calabrese C.R., Almassy R., Barton S., Batey M.A., Calvert A.H., Canan-Koch S., Durkacz B.W., Hostomsky Z., Kumpf R.A., Kyle S., Li J., Maegley K., Newell D.R., Notarianni E., Stratford I.J., Skalitzky D., Thomas H.D., Wang L.Z., Webber S.E., Williams K.J., and Curtin N.J. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J. Natl. Cancer Inst. 96 (2004) 56-67
20. Curtin N.J., Wang L.Z., Yiakouvaki A., Kyle S., Arris C.A., Canan-Koch S., Webber S.E., Durkacz B.W., Calvert H.A., Hostomsky Z., and Newell D.R. Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells. Clin. Cancer Res. 10 (2004) 881-889
21. Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., Kyle S., Meuth M., Curtin N.J., and Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434 (2005) 913-917
22. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., Santarosa M., Dillon K.J., Hickson I., Knights C., Martin N.M., Jackson S.P., Smith G.C., and Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 (2005) 917-921
23. Alano C.C., Kauppinen T.M., Valls A.V., and Swanson R.A. Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc. Natl. Acad. Sci. USA 103 (2006) 9685-9690
24. C. Szabo, P. Pacher, A. Swanson, Novel modulators of poly(ADP-ribose) polymerase. Trends Pharmacol. Sci. in press
25. Tamargo R.J., Bok R.A., and Brem H. Angiogenesis inhibition by minocycline. Cancer Res. 51 (1991) 672-675
26. Pacher P., and Szabo C. Role of poly(ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic complications: endothelial dysfunction, as a common underlying theme. Antioxid. Redox Signal 7 (2005) 1568-1580
27. Zheng L., Szabo C., and Kern T.S. Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-kappaB. Diabetes 53 (2004) 2960-2967
28. Obrosova I.G., Minchenko A.G., Frank R.N., Seigel G.M., Zsengeller Z., Pacher P., Stevens M.J., and Szabo C. Poly(ADP-ribose) polymerase inhibitors counteract diabetes- and hypoxia-induced retinal vascular endothelial growth factor overexpression. Int. J. Mol. Med. 14 (2004) 55-64
29. Racz I., Tory K., Gallyas Jr. F., Berente Z., Osz E., Jaszlits L., Bernath S., Sumegi B., Rabloczky G., and Literati-Nagy P. BGP-15-a novel poly(ADP-ribose) polymerase inhibitor-protects against nephrotoxicity of cisplatin without compromising its antitumor activity. Biochem. Pharmacol. 63 (2002) 1099-1111
30. Pacher P., Liaudet L., Bai P., Virag L., Mabley J.G., Hasko G., and Szabo C. Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. J. Pharmacol. Exp. Ther. 300 (2002) 862-867
31. Pacher P., Liaudet L., Mabley J.G., Cziraki A., Hasko G., and Szabo C. Beneficial effects of a novel ultrapotent poly(ADP-ribose) polymerase inhibitor in murine models of heart failure. Int. J. Mol. Med. 17 (2006) 369-375